Anton Bom, MD, PhD, FRCA[/one_fifth]
[four_fifth_last][framed_box]Anton Bom studied medicine at the Erasmus University, Rotterdam (The Netherlands). After having worked on cardiac afferent nerve fibres in cardiovascular reflexes at the Department of Cardiovascular Physiology in Düsseldorf (Germany), he joined the Department of Pharmacology of the Erasmus University and obtained his PhD cum laude for his thesis about the characterization of 5hydroxytryptamine receptors in the cardiovascular system.
Daniel Zollinger, PhD, PharmD[/one_fifth]
[four_fifth_last][framed_box]Daniel has more than 20 years international experience in pharmaceutical R&D. He was Director Clinical Research (CNS area) at Merck Sharp & Dohme, Oss and Research Manager at the ENMC (European NeuroMuscular Centre), a platform organization of European patient organizations in neuromuscular disorders.
Erik Sprengers, PhD, MD, MBA[/one_fifth] [four_fifth_last][framed_box]
Erik Sprengers has held numerous positions in the pharma industry, most recently as Head of Merck´s Translational Medicine Research Centre in Singapore.
Prior to that, he was VP Translational Medicine and VP Proof of Concept Team Office at the Schering-Plough Research Institute.
Thorsteinn Loftsson , PhD, PharmD
Thorsteinn received a M.S. Pharmacy (Pharmacist) degree from University of Copenhagen, Faculty of Pharmaceutical Sciences and M.S. and Ph.D. degrees from the Department of Pharmaceutical Chemistry at the University of Kansas.
Read more …